Here are the 424B prospectus supplements from ClearPoint Neuro, Inc. (CLPT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLPT filings page.
ClearPoint Neuro, Inc. has filed a resale prospectus covering up to 1,312,570 shares of its common stock that may be sold from time to time by former IRRAS Holdings, Inc. stockholders. ClearPoint is not selling shares in this offering and will receive no proceeds from any sales.
The registered shares were or will be issued as part of ClearPoint’s November 20, 2025 acquisition of IRRAS, a neurocritical care medical technology company. Consideration for the merger included $5,000,000 in cash and 1,119,404 ClearPoint shares, plus potential earnout payments. The 1,312,570 registered shares consist of 1,109,401 merger shares plus up to 203,169 holdback shares that may be released if no post-closing adjustments or indemnity claims reduce them.
ClearPoint is a commercial-stage medical device company focused on minimally invasive neurosurgery, including its ClearPoint Navigation System, operating-room focused SmartFrame platforms, and the ClearPoint Prism Neuro Laser Therapy System. Its biologics and drug delivery partnerships support more than 60 gene and cell therapy programs targeting direct delivery into the brain.